Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-17
DOI
10.1007/s11523-023-00999-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
- (2023) Jing Nie et al. Frontiers in Pharmacology
- Safety and management of niraparib monotherapy in ovarian cancer clinical trials
- (2023) Bradley J Monk et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Burden of ovarian cancer in China from 1990 to 2030: A systematic analysis and comparison with the global level
- (2023) Ying Wang et al. Frontiers in Public Health
- Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
- (2022) Roisin E. O'Cearbhaill et al. GYNECOLOGIC ONCOLOGY
- OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab
- (2022) Melissa M. Hardesty et al. GYNECOLOGIC ONCOLOGY
- Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)
- (2022) Ning Li et al. GYNECOLOGIC ONCOLOGY
- Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial
- (2021) X.H. Wu et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study
- (2021) Rishi Caleyachetty et al. Lancet Diabetes & Endocrinology
- Developing a validated nomogram for predicting ovarian metastasis in endometrial cancer patients: a retrospective research
- (2021) Xiaodie Liu et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer
- (2021) Zhenkun Wang et al. GYNECOLOGIC ONCOLOGY
- Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study
- (2021) Hong Zheng et al. MOLECULAR CANCER THERAPEUTICS
- An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions
- (2021) Melek Akay et al. Oncology and Therapy
- Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
- (2021) Philipp Harter et al. GYNECOLOGIC ONCOLOGY
- Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer
- (2021) Julia Paik Targeted Oncology
- Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
- (2021) Arnold Lee Targeted Oncology
- The forefront of ovarian cancer therapy: update on PARP inhibitors
- (2020) M.R. Mirza et al. ANNALS OF ONCOLOGY
- Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
- (2020) Paul DiSilvestro et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
- (2020) Yifan Jiang et al. Frontiers in Oncology
- 819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
- (2020) G. Valabrega et al. ANNALS OF ONCOLOGY
- Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
- (2019) Michel Fabbro et al. GYNECOLOGIC ONCOLOGY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study
- (2018) Irene Eriksson et al. Targeted Oncology
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
- (2012) L. C. Hanker et al. ANNALS OF ONCOLOGY
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started